J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca's Tagrisso, the go-to drug for a certain type of lung cancer.J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial. The company expects the benefit to be at least a year and possibly longer, J&J executives said in an interview. The company plans to present th ...